Research programme: PD-L1 siRNA therapy - Aligos Therapeutics
Latest Information Update: 18 Nov 2022
At a glance
- Originator Aligos Therapeutics
- Class Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Hepatitis B